A medication list template for kidney care solves a practical problem that affects almost every person with CKD: the challenge of tracking, communicating, and managing a medication regimen that is often more complex than almost any other chronic condition, changes frequently as the disease progresses, and requires accurate representation across multiple healthcare providers, pharmacies, and urgent care situations. The average CKD patient takes 10–15 medications simultaneously. New medications are added; doses are adjusted; some are discontinued; some require temporary holds for procedures or contrast imaging. Interactions between medications are clinically significant, and the addition of supplements or over-the-counter medications into the mix creates additional complexity. A comprehensive, well-maintained medication list is not a bureaucratic convenience — it is a patient safety tool. This article explains what a kidney care medication list should contain, how to maintain it accurately, and how to use it effectively across all clinical encounters. For understanding what the most common CKD medications do, the article on kidney disease medications: a simple overview provides accessible explanations. For the broader home monitoring framework that a medication list supports, see the article on home kidney health monitoring: what to track. For the clinical context of blood pressure medications specifically, see blood pressure medications and kidney protection.
What a Complete Kidney Care Medication List Must Include
A medication list for kidney care must be more detailed than the average patient medication list precisely because the stakes of medication errors in CKD are higher — impaired kidney clearance means drugs that are renally cleared accumulate to toxic levels more readily, and drug-drug interactions are more likely in a high-complexity polypharmacy regimen. Each entry on a kidney care medication list should include the following fields. Medication name (brand and generic): record both the brand name and the generic name if known. Different pharmacies may dispense generics from different manufacturers; emergency providers may use different formulary names; and the prescribing nephrologist, primary care provider, cardiologist, and endocrinologist may each use different nomenclature for the same drug. Having both names reduces the risk of miscommunication or duplication. Dose and unit: the exact dose — 5 mg, 10 mg, 500 mg — and the unit (milligrams, micrograms, international units). Dose adjustments in CKD are common, and the dose in the chart may differ from what was most recently dispensed if the prescribing provider changed it. The list should reflect the current dispensed dose, not the original prescription. Frequency and timing: once daily (morning or evening?), twice daily, three times daily, with meals, with water, before bed. Timing matters clinically — some antihypertensives are more effective at night; some phosphate binders must be taken with meals to work; some CKD medications require separation from calcium-containing foods or other medications. Prescribing provider: which provider prescribed this medication — nephrologist, primary care, cardiologist, endocrinologist? This is critical information in polypharmacy cases: when a change is needed, the patient and receiving provider both need to know who “owns” each medication and should be contacted for modifications. Indication (what it’s for): a brief description of why the medication is being taken — “blood pressure,” “phosphate control,” “anemia,” “water retention,” “bicarbonate supplement,” “immunosuppression.” Patients who understand why each medication is prescribed are more adherent and more likely to flag changes in symptoms that may be medication-related. Emergency providers need to know the indication to make safe prescribing decisions without full chart access. Start date and any dose changes: when the medication was started, and dates of any dose changes. If a potassium result spikes and the care team is reviewing the medication list, knowing that a potassium-sparing diuretic was increased two weeks ago is directly relevant. Allergies and adverse reactions: a separate section for all known medication allergies and significant adverse reactions — including the specific reaction (rash, angioedema, hyperkalemia, GI intolerance) not just “allergic.” This prevents re-prescription of medications with known adverse histories. The NIDDK guidance on medication management in CKD is at the NIDDK CKD management page. The NKF patient education on safe medication use in kidney disease is at the NKF CKD patient resource page.
Including Supplements and OTC Medications: Why They Cannot Be Left Off
One of the most common and consequential gaps in medication lists for CKD patients is the omission of supplements and over-the-counter (OTC) medications. The word “medications” in everyday usage is often interpreted as referring only to prescription drugs — leaving off the vitamin D capsule taken daily, the magnesium supplement added for leg cramps, the antacid used frequently for GI discomfort, and the ibuprofen taken occasionally for pain. In CKD, this omission creates specific and well-documented clinical risks. NSAIDs and kidney toxicity: ibuprofen (Advil, Motrin), naproxen (Aleve), and other non-steroidal anti-inflammatory drugs are among the most commonly used OTC pain relievers and are among the most nephrotoxic medications available without prescription. NSAIDs reduce renal prostaglandin production, which constricts the afferent arteriole, reduces GFR, and in CKD can precipitate acute kidney injury on top of chronic disease. Many CKD patients are not aware that ibuprofen and similar drugs are contraindicated in their condition. A medication list that includes “ibuprofen (occasional)” flags this to every provider who reviews the list — creating the opportunity for education and safer pain management alternatives. The clinical evidence on pain relievers and kidney safety is covered in the article on pain relievers and kidney safety and the companion article on NSAIDs and kidney risk. Magnesium-containing antacids: antacids that contain magnesium (Milk of Magnesia, some Maalox formulations) are widely available OTC and commonly used for GI symptoms. In advanced CKD, impaired magnesium excretion means these products can cause hypermagnesemia — and patients who are taking prescribed antacids or phosphate binders from the nephrologist may not know that OTC antacids can interfere. Supplements with drug interactions: as covered in the series on supplement safety for kidney patients, many supplements interact with prescription medications. St. John’s Wort with calcineurin inhibitors, high-dose vitamin K with warfarin, and potassium-containing supplements with ACE inhibitors or potassium-sparing diuretics are the highest-risk interactions. These interactions are only detectable if the supplement appears on the medication list that the pharmacist and prescribing providers review. Potassium content of supplements: patients on potassium restriction who are taking a multivitamin, sports nutrition product, or herbal supplement with significant potassium content may be unknowingly adding to their dietary potassium load. Listing every supplement with the dose and potassium content allows the renal dietitian to account for supplement-sourced potassium in the total dietary assessment. How to document supplements: use the same format as prescription medications — supplement name, dose per serving, frequency, what it’s for, and who recommended it. “Magnesium glycinate 400 mg at bedtime — for leg cramps — started per primary care recommendation” is a complete entry. The supplement safety framework for CKD is covered in the article on supplement safety for people with kidney disease. The KDIGO guidance on polypharmacy management in CKD is at the KDIGO CKD evaluation and management guidelines.
Keeping the List Current and Using It Across All Clinical Encounters
A medication list is only as useful as it is current. A list that was accurate six months ago may now be missing two new medications, contain a discontinued drug, and have outdated doses for three others — and that outdated list can cause clinical harm if used as the basis for prescribing decisions. Building the habit of updating the medication list at every medication change is the single most important maintenance practice. Triggers for updating the list: every time a new prescription is written; every time a dose is changed; every time a medication is discontinued; every time a new supplement or OTC medication is started or stopped. The update should happen on the same day as the change — not deferred to “when I get home” or “at the next appointment.” A simple rule: new prescription in hand → update the list before the prescription is filled. Carrying and sharing the list: the list should be carried at all times in a form that is accessible in an emergency — a folded paper copy in the wallet, a photo on the phone, or a medication card in the emergency contact section of the phone. In an emergency room setting, a readily accessible medication list can prevent dangerous prescribing interactions and accelerate clinical decisions. At every non-emergency medical encounter — primary care, specialist, urgent care, dentist, radiologist, emergency room — present the medication list before any new prescription is written or procedure is performed. Dental procedures require antibiotics that can interact with CKD medications; contrast imaging requires temporary holds on nephrotoxic medications; urgent care visits for infections require antibiotics prescribed at kidney-appropriate doses. Medication reconciliation at each appointment: at every nephrology appointment, bring the complete medication list and ask the nephrologist or nephrology nurse to reconcile it against the chart. Discrepancies between what is in the chart and what the patient is actually taking are common and clinically significant — the reconciliation appointment is the opportunity to close those gaps. Ask specifically: “Is there anything on this list that needs to be dose-adjusted based on my current kidney function?” As GFR declines, dose adjustments for renally cleared medications are required — and these adjustments are sometimes delayed if no one is systematically reviewing the list against the current creatinine and eGFR. Medication review with the pharmacist: beyond each individual prescriber’s knowledge, a clinical pharmacist has the broadest view of the complete medication regimen and its potential interactions. An annual comprehensive medication review with a pharmacist — particularly a pharmacist with CKD or nephrology experience — is a safety investment that catches interactions, duplication, and suboptimal dosing that no single prescriber may have seen in the context of the complete regimen. For patients integrating their medication list into the broader clinical appointment preparation process, the companion article on doctor visit checklist for kidney health provides a structured framework. The StatPearls reference on medication safety in CKD is at the StatPearls CKD reference.
Sources: NIDDK CKD Management · National Kidney Foundation · KDIGO CKD Guidelines · StatPearls: CKD Medications
Common CKD Medication Categories and Why Each Requires Careful Documentation
Understanding the major categories of medications commonly prescribed in CKD helps patients document their list more accurately and understand why each category requires careful tracking. CKD treatment typically involves medications across multiple therapeutic categories simultaneously, and the interactions between categories are clinically significant. Antihypertensives: the largest and most complex medication category in CKD. ACE inhibitors (lisinopril, ramipril, enalapril) and ARBs (losartan, valsartan, olmesartan) are the preferred first-line agents in CKD with proteinuria because they reduce glomerular pressure and proteinuria independently of blood pressure effects — not just blood pressure medications but kidney-protective agents. SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) have emerged as important kidney-protective medications in diabetic nephropathy and CKD with proteinuria. Calcium channel blockers (amlodipine, diltiazem), beta-blockers, and diuretics are also commonly used. A patient on multiple antihypertensives needs the exact doses and timing documented because small dose changes can shift blood pressure control significantly. Diuretics: loop diuretics (furosemide, torsemide, bumetanide) are commonly prescribed for fluid management in CKD. Thiazide diuretics are used in earlier CKD stages. Potassium-sparing diuretics (spironolactone, eplerenone) add hyperkalemia risk when combined with ACE inhibitors or ARBs. The specific diuretic, dose, and timing must be documented precisely — “furosemide 40 mg in the morning” vs. “furosemide 80 mg twice daily” represent very different therapeutic situations. Phosphate binders: patients with advanced CKD develop hyperphosphatemia requiring phosphate binders (calcium carbonate, sevelamer, lanthanum carbonate, ferric citrate). Phosphate binders must be taken with meals to absorb dietary phosphate — timing is as important as dose. The type of binder matters: calcium-based binders contribute to calcium load (relevant to cardiovascular calcification risk in CKD), while non-calcium binders do not. Vitamin D and mineral metabolism agents: cholecalciferol (vitamin D3) for nutritional vitamin D deficiency, and active vitamin D analogues (calcitriol, paricalcitol, doxercalciferol) for secondary hyperparathyroidism in CKD stages 3–5. The distinction between nutritional vitamin D and active vitamin D analogues is clinically important — they have different indications, different monitoring requirements, and different dosing. Both should be on the medication list with their specific form specified. The clinical context for vitamin D in kidney disease is covered in the article on vitamin D and kidney disease. Erythropoiesis-stimulating agents and iron: CKD-associated anemia is managed with ESAs (epoetin alfa, darbepoetin alfa) and iron supplementation (ferrous sulfate orally, or intravenous iron preparations in dialysis patients). The dosing of ESAs is adjusted based on hemoglobin response — precise tracking of the current dose and administration schedule is important for the care team managing anemia treatment. Iron supplements interact with many medications by reducing absorption — phosphate binders, thyroid medications, fluoroquinolone antibiotics — and must be timed appropriately. Bicarbonate supplements: metabolic acidosis is common in advanced CKD, treated with sodium bicarbonate tablets. Bicarbonate doses are adjusted based on serum bicarbonate levels and have important kidney-protective effects beyond acid-base correction. The current dose and recent changes should be documented with the context of the latest serum bicarbonate result. Immunosuppressants (transplant recipients): transplant medications — tacrolimus, cyclosporine, mycophenolate mofetil, prednisone, azathioprine — have the narrowest therapeutic windows of any medications CKD patients take. Tacrolimus and cyclosporine levels are directly monitored because their therapeutic range is measured in nanograms per milliliter — tiny dose changes have large clinical effects, and interactions with dozens of drugs and foods (including grapefruit) can significantly alter levels. A transplant recipient’s medication list is typically the most complex of any CKD patient and requires the most precise documentation. The NIDDK resource on CKD medication management is at the NIDDK CKD management page. The article on medication safety for kidney patients covers the safety framework for managing complex CKD medication regimens.
Special Situations: Procedure Preparation, Travel, and Emergency Scenarios
A kidney care medication list serves its most important safety function in three specific situations that arise regularly: before procedures and imaging studies, when traveling, and in emergency or urgent care scenarios. Each situation has distinct requirements that a well-maintained medication list directly addresses. Before procedures and contrast imaging: several common CKD medications must be temporarily held before procedures, particularly those involving iodinated contrast media (CT scans with contrast, cardiac catheterization, some angiography studies). Metformin — used in CKD patients with diabetes — must be held 48 hours before and after contrast administration because contrast-induced kidney injury combined with metformin can rarely cause lactic acidosis. ACE inhibitors and ARBs are sometimes held before major surgery or procedures with fluid shifts. NSAIDs (if erroneously prescribed) are contraindicated with contrast. The radiologist and proceduralist reviewing the medication list can identify these holds; a patient who presents without a list may have medications that should be held go unrecognized. The contrast nephropathy risk in CKD is covered in the article on CT scan for kidney and urinary problems. When traveling: traveling CKD patients should carry at minimum a two-week supply of all medications (not stored entirely in checked luggage, given the risk of loss), a current printed medication list translated into the local language if traveling internationally, and contact information for the prescribing nephrologist. A photo of the medication list on the phone ensures it is accessible even if the printed copy is lost. For dialysis patients, traveling requires advance coordination with dialysis centers at the destination — a detailed medication list is typically required by the receiving dialysis center. In emergency and urgent care scenarios: a patient presenting to an emergency room unconscious, confused, or unable to communicate relies entirely on the information they are carrying. A medication list kept in the wallet, on a medical alert card, or on a phone lockscreen provides the emergency team with the complete medication context needed to make safe, rapid treatment decisions. Emergency rooms regularly administer medications that can interact harmfully with CKD drugs — without a medication list, these interactions may not be recognized. For patients organizing all their CKD management documents including medication lists, blood pressure logs, and appointment preparation materials into a unified approach, the article on long-term kidney care plan provides the broader organizational framework. The KDIGO guidelines reference for CKD management is at the KDIGO CKD evaluation and management guidelines.
Digital Tools and Paper Formats: Choosing What Works for You
The format of a kidney care medication list — digital or paper — matters less than its completeness, accuracy, and accessibility. Both formats have genuine advantages, and many CKD patients use a combination. Paper formats: a printed or handwritten medication list on a single page is universally accessible, requires no battery, and can be read by any healthcare provider regardless of software. A laminated wallet card with the complete medication list is the most portable format for emergency situations. The disadvantage of paper is the update challenge — a paper list that is not updated with each medication change quickly becomes outdated. Keeping a master digital copy and printing an updated version at each medication change solves this problem. Smartphone apps: dedicated medication tracking apps (Medisafe, CareClinic, MyTherapy, Apple Health or Google Health medication tracking) can store complete medication lists with doses, frequencies, prescribers, and reminders. Most allow the list to be exported as a PDF for printing or sharing. The advantages include automatic reminders, easy updates, and cloud backup. The disadvantages include dependence on a charged phone and the need to navigate app interfaces in high-stress situations. Patient portal tools: many health systems now offer medication list management within the patient portal (Epic MyChart, Cerner patient portals). These portals sync with the prescribing system and may automatically update when a new prescription is written. The limitation is that portal medication lists often don’t include supplements, OTC medications, or medications prescribed outside the health system — making them incomplete for CKD patients with multiple providers across different systems. Hybrid approach: maintaining a comprehensive master list in a notes app or word processor document — updated immediately with every medication change — and printing a current version at each appointment, plus keeping a laminated wallet card, gives the advantages of digital accuracy and paper accessibility. The regular appointment review for CKD management described in the companion article on doctor visit checklist for kidney health includes medication list reconciliation as a standard step. The NKF resource on managing CKD day to day is at the NKF CKD patient resource page.
I had a serious wake-up call last year when I went to urgent care for a sinus infection and they prescribed ibuprofen for the fever. I didn’t know it was contraindicated in CKD and I hadn’t flagged my kidney disease because the urgent care was for a different problem. My creatinine jumped at my next nephrology visit and my nephrologist figured out what had happened. I now carry a printed medication list that specifically notes ‘NO NSAIDs — CKD stage 3b’ at the top. The point about presenting the list before any new prescription is written is exactly the right approach.
Ellen, the urgent care NSAID situation you describe is unfortunately common — and it is exactly the scenario that the ‘present the list before any prescription is written’ rule is designed to prevent. Emergency and urgent care providers typically see patients outside of their usual clinical context and rely entirely on what the patient presents or reports. ‘NO NSAIDs — CKD stage 3b’ as a header note on the medication list is an excellent safety addition — it ensures the contraindication is visible even in a rushed clinical situation where the full list might not be reviewed carefully. Your pharmacist can also add a ‘NSAID — CONTRAINDICATED’ flag to your medication profile, which may alert the pharmacist if a provider calls in an NSAID prescription.
The point about tracking which provider prescribed each medication is something I didn’t do until after a confusing incident where my transplant nephrologist changed a tacrolimus dose and my primary care doctor, not knowing about the change, called in a refill for the old dose. I now list the prescribing provider for every medication and have explicit notes about who to contact before any changes. Polypharmacy after transplant is genuinely complicated and the medication list is the only tool that keeps all the providers on the same page.